CYCN - CIK 0001755237
The table below shows Cyclerion Therapeutics, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.82M | $4.57M | $3.01M | $3.64M | $2.87M | $4.59M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | $0.00 | $100.00K | $525.00K | $581.00K | $44.00K | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $3.09M |
| $5.07M |
| $4.02M |
| $4.50M |
| $3.55M |
| $4.71M |
| Property, plant & equipment | $66.00K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Goodwill | - | - | - | - | - | - |
| Total assets | $8.51M | $10.41M | $9.37M | $9.85M | $8.90M | $10.06M |
| Accounts payable | $457.00K | $480.00K | $462.00K | $483.00K | $304.00K | $651.00K |
| Total current liabilities | $1.71M | $877.00K | $800.00K | $1.07M | $700.00K | $1.28M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | - | - | - | - | - | - |
| Retained earnings | -$274.20M | -$270.22M | -$269.25M | -$268.92M | -$268.02M | -$267.30M |
| Total equity | $6.79M | $9.54M | $8.57M | $8.78M | $8.20M | $8.78M |